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ABSTRACT
B-cell acute lymphoblastic leukemia is the most common pediatric cancer, responsible
for the most cancer-related deaths in children. Advances in chemotherapy over the past
half-century have steadily increased the remission and survival of children with B-cell
acute lymphoblastic leukemia to nearly 90%. However, the problems of minimal
residual disease and relapsed and refractory disease persist. Personalized, targeted
therapies have improved outcomes among the minority of patients for whom
chemotherapy is ineffective. Immunotherapy, specifically bispecific T-cell engaging
antibody therapy and chimeric antigen receptor T-cell therapy, has proven an effective
treatment for relapsed and refractory B-cell acute lymphoblastic leukemia in children.
These new modalities, however, have also introduced new adverse side effects to the
treatment regimen. Though immunotherapy has increased remission and survival, more
work must be done to reduce adverse effects and eliminate relapsed and refractory
disease.
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First described in 1913 in the New York Times as "acute lymphatic leukemia"
(Bakalar 2012), acute lymphoblastic leukemia (ALL) is a malignancy of the blood that
occurs when lymphoid progenitor cells transform and proliferate, overtaking the bone
marrow, blood, and extramedullary sites (Terwilliger and Abdul-Hay 2017). Though its
incidence is bimodal, with one peak in children and another peak in adults above age 50,
ALL is the most common pediatric cancer, with 80% of ALL occurring in children
("Cancer Statistics Review, 1975-2013 - Previous Version - SEER Cancer Statistics
Review" n.d.). Historically a fatal disease, survival rates for childhood ALL have
increased dramatically over the past 50 years, from a mere 20% in 1961 to 90% today
(Pui and Evans 2013) . Despite advances in our understanding of the biology of ALL
and resulting improvement of treatment regimens, ALL persists as the most common
cause of cancer-related deaths in children (Holmfeldt et al. 2013).
Improvements in ALL treatment over the decades have been consistent and
significant. Aminopterin, a folic acid antagonist, was the first treatment to achieve
"temporary remissions" in ALL patients in the mid-20th century (Farber and Diamond
1948). Although this initial trial was small and the results were modest, it stands as the
pioneering use of chemotherapy to treat childhood ALL (Pui and Evans 2013). In 1962,
researchers at St. Jude Children's Research Hospital established what stands to this day
as the "backbone" of ALL treatment (Pinkel 1971). Their "total therapy" regimen
consisted of three components: remission induction, intensification/consolidation, and
continuation/maintenance therapy. Subsequent modifications on this treatment
protocol nearly doubled cure rates in the following two decades, with steady
improvement in outcome into the 21t century.
4
With continued advances in our understanding of the biology of ALL, the
problem of precisely defining the disease in all its manifestations has become more
complex, but the advances in treatment likewise have become more nuanced and
personalized to each subtype. Significant as these improvements are, the problem of
relapsed and refractory disease remains. Here, we will examine the etiology and current
treatment regimens for childhood B-cell ALL as well as recent advances in
immunotherapy, specifically bispecific T-cell engaging antibody therapy and chimeric
antigen receptor T-cell therapy.
II. Childhood Acute Lymphoblastic Leukemia
a. Etiology & Prognosis
Like most cancers, ALL is a heterogeneous malignancy without a single common
causative transforming event. Transformed cells are of the lymphoid lineage, with cells
that normally differentiate from lymphoid stem cells to B- and T-lymphoblasts and
eventually mature into B- and T-lymphocytes. B-cell ALL manifests as an accumulation
of malignant, immature B-cells in the blood, bone marrow, and extramedullary
tissue. Though researchers have identified many chromosomal aberrations necessary for
transformation (discussed in detail below), a combination of exposures, inherited
genetic variation, and chance probably contribute to disease initiation. Studies on
exposure to radiation in utero or later weakly correlate with a greater risk for developing
ALL, but these studies have not been reproducible (Inaba, Greaves, and Mullighan
2013). Certain genetic syndromes (Down syndrome, Fanconi anemia, Bloom syndrome,
ataxia telangiectasia, and Nijmegen breakdown syndrome) increase the risk
for developing ALL (Terwilliger and Abdul-Hay 2017). Genome-wide association studies
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have identified germline allelic variants in four genes that significantly associate with
childhood ALL. These genes (IKZF1, ARID5B, CEBPE, and CDKN2A) encode regulators
of lymphocyte differentiation and proliferation (Papaemmanuil et al. 2009; Sherborne
et al. 2010). Despite its heterogeneity, there are common subtypes of B-cell ALL whose
genetic lesions have been identified and studied.
Aneuploidy was one of the first cytogenetic aberrations identified in B-cell ALL
and serves as a means of risk stratification in patients. Patients with hypodiploid B-cell
ALL are known to be a high-risk subgroup, but hypodiploidy itself can be further
stratified according to the number of chromosomes. Disease can be classified as
near haploid (24-31 chromosomes), low-hypodiploid (32-39 chromosomes), or high-
hypodiploid (40-43 chromosomes), though this is a rare subgroup (Pui and Evans
2013). While hypodiploidy describes many thousands of genetic changes, these
classifications do not distinguish between "driver" mutations in leukemogeneis and
"passenger" mutations that accumulate after transformation (Pui et al. 2011). Genome-
wide studies revealed that each class of hypodiploidy has a unique genetic basis for
disease. Alterations in receptor tyrosine kinase signaling and Ras signaling characterize
near-haploid disease while alterations in TP53 and RB1 characterize low-hypodiploid
disease (Holmfeldt et al. 2013).
Chromosomal translocations have been most telling about the mechanism of
disease initiation, though each alone are not sufficient to generate leukemia (Terwilliger
& Abdul-Hay 2017). One famous chromosomal translocation, first reported in 1970, is
the Philadelphia chromosome, resulting in the BCR-ABL fusion protein (Propp and Lizzi
1970). Normally a tightly regulated tyrosine protein kinase, ABL becomes constitutively
active when fused with BCR. The fusion protein leads to aberrant proliferation and
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promotes survival and self-renewal. Another common fusion protein is TEL-AML1.
Made of TEL, an ETS family transcription factor required for homing lymphoid cells to
the bone marrow, and AML1, the DNA-binding subunit of core-binding factor that
recruits transcription factors to activate Hox genes, this fusion protein inhibits
transcription, leading to altered self-renewal, proliferation, and differentiation in
lymphoid cells (Loh and Rubnitz 2002). Most deadly are diseases carrying an MLL-
fusion protein. MLL is a nuclear protein responsible for maintaining expression of
certain HOX genes. Fusion with one of its 40 known partners yields a dominant gain-of-
function protein that enhances HOX transcription (Ernst, Wang, and Korsmeyer 2002).
Over 8o% of infants with B-cell ALL harbor an MLL-fusion protein.
Clinically, symptoms of ALL can be nonspecific but result from malignant
lymphoid progenitor cells accumulating in the blood, bone marrow, and extramedullary
sites (Terwilliger and Abdul-Hay 2017). Signs of bone marrow failure include anemia,
thrombocytopenia, and leukopenia. ALL cells in extramedullary sites cause
lymphadenopathy, splenomegaly, or hepatomegaly. Their presence in the CNS presents
as cranial nerve deficits or meningismus. In addition to these symptoms,
patients also experience fever, weight loss, and night sweats (together referred to as 'B
symptoms') as well as fatigue, dyspnea, and easy bleeding or bruising. Clinicians
diagnose ALL when the patient harbors at least 20% lymphoblasts in the bone marrow
or peripheral blood (Alvarnas et al. 2015). Following initial diagnosis, clinicians further
characterize the disease using flow cytometry, immunophenotyping, and cytogenetic
testing to assess the patient's risk and determine the best method for treatment.
As previously mentioned, the standard of care for B-cell ALL is a chemotherapy
regimen first established in the 196os. Induction of remission,
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intensification/consolidation, and continuation/maintenance therapy typically span two
to two-and-a-half years. Patient response depends both on biological features of their
disease and patient-specific pharmacokinetics (Inaba, Greaves, and Mullighan 2013).
Some patients, for example, carry one or two nonfunctional copies of the thiopurine
methyltransferase gene. Thiopurine methyltransferase is necessary to metabolize
mercaptopurine, a chemotherapeutic agent. Without this metabolism, normal
mercaptopurine doses put patients at greater risk for hematopoietic
toxicity. Recognizing this pitfall, clinicians began assigning individualized dosing to
patients with this genetic variation, to great success (Pui and Evans 2013). Personalized
treatment went a step further when the tyrosine kinase inhibitor imatinib (and
later, dasatinib) was incorporated into frontline therapy to treat Philadelphia-
chromosome-positive B-cell ALL (Schultz et al. 2009). This subtype, once associated
with a poor prognosis, now boasts complete remission rates greater than 90%, attesting
to the efficacy of personalized treatment.
b. Limitations of Conventional Therapy
Cure rates in children have increased steady over the last half-century, but those
whose disease relapses have a prognosis that has not changed at the same pace.
Although complete remission rates have approached 90%, the remaining 10% of
pediatric patients whose disease is relapsed or is refractory to treatment have not had
many options for more effective treatment (Pierro et al. 2017). The approach to treat
relapsed and refractory B-cell ALL is unimaginative: reinduction is usually more of the
same chemotherapeutic drugs but in a modified schedule or more intense dose (Pierro
et al. 2017). The aim of reinduction therapy, however, is not to cure the patient, but to
induce remission for long enough to make them eligible for an allogenic hematopoietic
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cell transplantation (Luskin and DeAngelo 2017). Unfortunately, even this final line of
attack is ineffective, and many patients who receive transplants have poor outcomes.
Relapsed or refractory disease arises from a Darwinian selection driven by the
chemotherapeutic agents themselves. Studies comparing the B-cell ALL clones present
at diagnosis to those present at relapse have shown that 94% of relapsed clones arose
from a clone present at diagnosis and not from a newly initiated disease (Mullighan et
al. 2008). Minimal residual disease that survives the initial treatment regimen may
carry mutations that confers resistance to chemotherapy. Relapsed clones can be
resistant glucocorticoids via mutations in genes involved in glucocorticoid signaling
like NR3C1, BTG1, and TBL1XR1 (Klumper et al. 1995). Other mutations-
like MSH6 and NT5C2-have been associated with resistance to thiopurines (Pierro et
al. 2017). Resistance to these chemotherapeutic agents demonstrates the selective
pressure these agents place on disease.
Reinduction therapy is unsuccessful not only because of intrinsic resistance to
the chemotherapeutic agents but also because of the toxicity associated with
this aggressive treatment. Increasing dose may have modest effects on disease burden,
but eventually mortality due to toxicity will supersede the disease as the cause of death
(Biondi et al. 2017). Immunotherapy is a promising alternative approach to fighting
relapsed and refractory disease.
III. Immunotherapy
With both innate and adaptive arms, the immune system has evolved to both
generally and specifically defend against infection. As efficient and complex as the
adaptive immune system is, it is not above manipulation. Immunotherapy capitalizes on
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the adaptive immune system, either by enhancing the natural cellular response against
cancer cells or by synthetically targeting immune cells to destroy cancer cells. In the
crusade against ALL, the synthetic approach has yielded promising results by
commandeering T lymphocytes in a manner that bypasses their natural limitations
but exploits their natural activity.
a. T-Cell Activation
T lymphocytes, or T-cells, are part of the adaptive immune system, patrolling the
body for foreign antigens and leading multi-cell crusade of eliminating infected cells. T-
cell receptors on the surface of T-cells recognize peptide antigens presented by the
major histocompatibility complex (MHC) protein at the surface of somatic cells. All
nucleated cells express MHC class I, which presents endogenous antigens at the
cell surface. CD8+ T-cells, known as cytotoxic T-cells, recognize MHC class I and their
associated antigens. Only professional antigen-presenting cells express MHC class II,
which presents exogenous antigens, indicating infection. CD4+ T-cells, known as helper
or regulatory T-cells, recognize MHC class II and their associated antigens. MHC
recognition by the T-cell receptor, however, is not sufficient to activate a T-cell. Naive T-
cells require a co-stimulatory molecule (CD28) to also engage with the antigen-
presenting cell. Without this second signal, T-cells are susceptible to anergy, or
desensitization to the antigen. Engagement of the MHC with the T-cell receptor and the
co-stimulatory molecule creates an immune synapse. The T-cell receptor and the co-
stimulatory molecule come into close proximity to one another, initiating a cascade of
intracellular signaling that leads to T-cell activation (Owen et al. 2009).
Once activated, T-cells undergo clonal expansion and differentiation, ultimately
maturing into their full effector functions. Immediately after activation, both CD4+ and
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CD8+ T-cells secrete cytokines that aid in the subsequent immune response and in T-
cell maturation. Cytokines released by CD4+ helper T-cells stimulate clonal expansion of
the T-cell and recruit and activate other immune cells to kill target cells. Cytokines
released by CD8+ cytotoxic T-cells stimulate clonal T-cell expansion, and target cell
killing, as well as the recruitment and activation of other immune cells to kill target
cells. Thus, T-cells defend the body in two ways: by regulating effector response from
other immune cells and by directly attacking target cells (Owen et al. 2009).
b. BiTEs
A bispecific T-cell engaging antibody (BiTE) engages T-cells to destroy ALL cells
by physically juxtaposing T-cells and ALL cells and activating the T-cells. Made up of the
variable antigen-binding domains of two antibodies linked by a peptide, BiTEs capitalize
on the high affinity and avidity of antibodies to their antigens (Ribera et al. 2015).
Blinatumomab, a BiTE from Amgen Inc currently used to treat relapsed or refractory
ALL, binds T-cells with an anti-CD3 arm and ALL cells with its anti-CD19 arm. CD19 is
expressed by all B cells. Unlike with the natural T-cell response described above, CD19
does not need to be presented by the MHC for the T-cell to be activated. By forcing the
ALL cells and T-cells into such close proximity, Blinatumomab leads to the formation
of an immune synapse and hence the destruction of the ALL cell (Aldoss et al. 2017).
In practice, Blinatumomab is an effective therapeutic modality both because of its
function and because of its structure. Because its function is based on highly specific
antibody-antigen binding, Blinatumomab is clinically efficacious at picomolar
concentrations (Nagorsen et al. 2012). In addition, because its mechanism of action
relies on T-cell activation, Blinatumomab's effects are increased by signal amplification
from the T-cell receptor (Aldross et al 2017). Not only is it mechanistically potent, but its
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structure makes it especially practical in the clinic. Because Blinatumomab is made up
of two variable antigen-binding regions and a peptide linker, it is about one-third the
size of an antibody (Nagorsen et al. 2012). Its minuscule size means that Blinatumomab
has a short serum half-life. Though its rapid clearance means it must be administered by
continuous intravenous infusion, it also gives clinicians the flexibility to halt treatment
should the side effects be particularly dangerous.
Administration of Blintumomab yields results that logically flow from the T-cell
activation theory. Although levels of circulating B- and T-cell drop immediately after
initial infusion (Zhu et al. 2017), effector T-cell levels exceed normal levels within a few
days. Levels of both CD4+ and CD8+ effector T-cells increase, but levels of naive T-cells
remain stagnant. This is not surprising since Blintumomab is facilitating the activation
and subsequent clonal expansion and differentiation of T-cells. Also not surprising is
the hypogammaglobulinemia that follows treatment. Blintumomab targets T-cells
toward any CD19-expressing cells, which are not only B-cell ALL but also normal B
lymphocytes and plasma precursors. Though expected, this effect puts patients at
greater risk for infection because although naive B cells recover from this depletion,
mature B cells and plasma cells do not (Zugmaier et al. 2014).
Blintumomab is effective at treating relapsed and refractory B-cell ALL in children,
as demonstrated by clinical trials. In one trial, 39% of patients achieved complete
remission and 52% of those patients tested negatively for minimal residual disease (von
Stackelberg et al. 2016). However, the efficacy of Blintumomab comes at a cost. Two
major adverse effect of Blintumomab treatment are cytokine release syndrome and
neurotoxicity (Aldoss et al. 2017). Patients with high leukemic burden at initiation of
treatment were more likely to experience cytokine release syndrome, but pretreatment
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with dexamethasone proved an effective prophylaxis (Topp et al. 2014). Neurotoxicity
presented in adult patients more frequently than in children and could likewise be
mitigated using dexamethasone. Thus although side effects of Blintumomab are not
mild, they are manageable.
c. CAR T-Cell Therapy
Like BiTEs, chimeric antigen receptor (CAR) T-cells use antibody affinity to CD19
to juxtapose T-cells and B-cell ALL cells. The T-cells involved in this interaction, unlike
with BiTEs, are themselves genetically modified to exclusively target CD19. Rather than
rely on the T-cell receptor recognizing an antigen presented by MHC, CARs replace the
extracellular domain of the T-cell receptor with the single-chain variable fragment of a
monoclonal antibody targeting CD19. The transmembrane and intracellular portions of
the T-cell receptor are unaltered, but CAR T-cells also express a co-stimulatory domain,
either 4-1BB or CD28. Though the extracellular single-chain variable fragment is
sufficient to bring the T-cell and target cell into close proximity, the co-stimulatory
domain is necessary for T-cell activation, expansion, and persistence (Savoldo et al.
2011; Campana, Schwarz, and Imai 2014). These T-cells are isolated from the patient
by leukapheresis, transduced with the CAR vector, expanded, then re-infused into the
patient a few weeks later (Aldoss et al. 2017).
Complete remission rates in pediatric patients with refractory and relapsed B-cell
ALL treated with CAR T-cell therapy far exceed those achieved by Blintumomab. The
most successful trial to date was a collaboration between the University of Pennsylvania,
Children's Hospital of Philadelphia, and Novartis using their recently FDA-approved
CTLo19 CAR T-cell therapy (Grupp et al. 2015). This trial was conducted on 30 high-risk
patients, 25 of whom were children. Only 3 of the patients enrolled in this trial had
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primary refractory disease: 18 patients had relapsed after allogenic hematopoietic stem
cell transplantation and three patients were refractory to blinatumomab. Despite these
seemingly impossible hurdles, CTLoi9 achieved complete remission in 90% of the
patients. Even more impressive, 15 of the patients who went into complete remission did
not receive further therapy (Maude et al. 2014).
As remarkable as the final results were, the patients experienced serious toxicities
during treatment. Just as with Blintumomab, the main adverse effects of CAR T-cell
therapy are cytokine release syndrome and neurotoxicity. Most patients experienced
mild symptoms of cytokine release syndrome within the first 2 weeks of treatment.
These symptoms were successfully mitigated using fluids and antipyretics (Luskin and
DeAngelo 2017). Some patients, however, experienced more severe symptoms including
high fever, respiratory distress, and organ failure (Maude et al. 2014). Neurotoxicity,
manifesting as confusion, is another result of cytokine release syndrome. Though
neurotoxicity is usually manageable, one CAR T trial by Juno Therapeutics reported a
fatal cerebral edema and herniation (Keshavan and Garde 2016). The question of why
Juno Therapeutics' CAR T therapy yielded such an extreme adverse event where as
Novartis' CAR T therapy did not remains unanswered.
d. Limitations of Immunotherapy
Despite its unique approach to treating patients with relapsed and refractory B-
cell ALL, immunotherapy in its current state is not the saving grace for all patients. Both
Blinatumomab and CAR T-cell therapy yield better outcomes for patients who at the
start of treatment had lower leukemia burden (Aldoss et al. 2017). Even when the
therapy is effective for patients with particularly aggressive disease, relapse following
immunotherapy can present as a new disease. The specificity of Blinatumomab and CAR
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T-cell therapy is a double-edged sword, simultaneously allowing for a strong targeted
attack but limiting the effort to attacking only CD19+ cells. B-cell ALL's heterogeneity
and propensity to mutate persist as challenges to therapy.
In the case of Blinatumomab, relapse has been linked both to limitations of its
own activity as well as to a changing disease profile. B-cell ALL presents in the bone
marrow, blood, and extramedullary sites, and while Blinatumomab is effective at
eliminating disease in the blood and bone marrow, it has been observed to have less
activity in extramedullary sites (Topp et al. 2014). Consequently, in patients who relapse
following Blinatumomab treatment, extramedullary relapse is over-represented. Even
when Blinatumomab is effective in all sites of disease burden, the disease itself may
become resistant to the treatment. In 10-15% of relapse cases following Blinatumomab,
relapsed disease was CD19-negative (Topp et al. 2012). One study described a patient
who received Blinatumomab treatment twice, relapsing after both instances. Following
the second relapse after Blinatumomab, her disease had lost nearly all B-cell markers
including CD19, manifesting instead with a myeloid phenotype (Zoghbi et al. 2017). As
was the case with chemotherapy resistance, the selective pressure of Blinatumomab
resulted in a disease totally resistant to the treatment.
CAR T-cell therapy shares some limitations with Blinatumomab and has its own
unique drawbacks. Just like Blinatumomab, CAR T-cell therapy exclusively targets
CD19-expressing cells, making the treatment ineffective against CD19- ALL.
Investigators at the National Cancer Institute are tackling this hurdle head-on by
developing CAR T-cells bearing anti-CD22 single-chain variable fragment. CD22,
another B-cell-specific antigen, has proven to be an effective means of targeting CD19-
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ALL. In a trial with relapsed pediatric patients, the majority of whom had relapsed
following anti-CD19 CAR T-cell therapy and harbored CD19- disease, anti-CD22 CAR T-
cell therapy resulted in minimal residual disease-negative complete remission in 8 out
of 10 participants (Shah et al. 2016). The CAR T modality thus lends itself to
modification depending on the patient's needs. However, this property can also be
limiting: because CAR T-cells must be produced anew for each patient, treatment for
this rapidly progressing and rapidly mutating disease is not immediate. In addition to
keeping patients stable as they await their CAR T-cell infusion, hospitals also bear the
burden of the intensive care required when patients inevitably experience the adverse
effects associated with CAR T-cell therapy. Though these drawbacks make CAR T-cell
therapy an expensive and risky treatment option, the results speak for themselves.
IV. Conclusion
Childhood B-cell acute lymphoblastic leukemia has been steadily approaching a
cure over the past half century of biological research and treatment advancements.
Though frontline therapy has persisted as the cause of remission for most patients, the
small fraction of pediatric patients with relapsed or refractory disease have a growing
number of treatment options that target their unique malignancy. Advancements in
immunotherapy through the development of bispecific T-cell engaging antibodies and
chimeric antigen receptor T cell therapy have extended the lifespans of patients who less
than a decade ago would have had a dire prognosis. As researchers continue to refine
their understanding of the biology of this complex disease and concurrently refine their
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treatment strategies, patients can look forward not only to longer survival, but to less
toxicity during therapy.
Remission and survival rates of patients treated with BiTEs or CAR T-cell therapy
are promising, but there is much room for improvement in both of these modalities.
Currently, both Blinatumomab and anti-CD19 CAR T-cell therapy are approved for use
only in patients with relapsed or refractory disease. However, both of these modalities
function through mechanisms distinct from frontline chemotherapy and could therefore
potentially work synergistically with frontline therapy if administered early on. There is
an ongoing phase II clinical trial (NCT02143414) assessing the efficacy of
chemotherapy, Blinatumomab, and dasatinib combination therapy in geriatric patients
with B-cell ALL. The drawback of administering immunotherapy early on is the
potentially unnecessary risk of severe toxicity (cytokine release syndrome,
neurotoxicity) associated with these modalities in addition to the toxicity patients
experience with chemotherapy alone. While it is preemptive to suggest that
immunotherapy be administered as frontline therapy for all patients, further refinement
of patient risk stratification can help clinicians predict the progression of disease and
appropriately weigh the risk of adverse events with the potential for remission without
relapse. For example, one issue with CAR T-cell therapy is the length of time patients
must wait for their cells to be ready for infusion. Perhaps more accurate risk
stratification could eventually lead clinicians to preemptively collect and engineer T cells
from a patient likely to relapse following frontline therapy. This future may not be far off
given the pace of advancement and motivation to finally cure ALL.
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